These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15535307)

  • 21. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
    Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
    Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
    Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
    Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel in the management of ovarian cancer.
    Blagden SP; Kaye SB
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel].
    Yoshida M; Ohtsu A
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():404-8. PubMed ID: 11424415
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of recurrent ovarian cancer].
    Kudo R; Sagae S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1991-7. PubMed ID: 1358032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment for recurrent ovarian cancer. A report of 2 cases.
    Maxwell AM; Jordaan JP
    S Afr Med J; 1987 Feb; 71(3):180. PubMed ID: 3810370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
    Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK
    Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
    Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
    Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
    Meerpohl HG
    Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemotherapy for ovarian cancer--introduction].
    Yamada H; Sugiyama T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():540-5. PubMed ID: 15535304
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chemotherapy for recurrent ovarian cancer].
    Nishimura H; Imamura K; Chang C
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
    Ozols RF
    J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
    Hwang JH; Yoo HJ; Lim MC; Seo SS; Park SY; Kang S
    Anticancer Drugs; 2012 Mar; 23(3):321-5. PubMed ID: 22156765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.